1-10 of 10
Mark Offer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.

Simon DJ Gibbs, Julian D Gillmore, Prayman T Sattianayagam, Mark Offer, Helen J Lachmann, Philip N Hawkins, Ashutosh D Wechalekar
Journal: Blood
Blood (2009) 114 (22): 745.
https://doi.org/10.1182/blood.V114.22.745.745
Published: 2009
Journal Articles

Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?.

Simon DJ Gibbs, Prayman T Sattianayagam, Julian D Gillmore, Mark Offer, Helen J Lachmann, Philip N Hawkins, Ashutosh D Wechalekar
Journal: Blood
Blood (2009) 114 (22): 1863.
https://doi.org/10.1182/blood.V114.22.1863.1863
Published: 2009
Journal Articles

Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.

Si mon DJ Gibbs, Prayman T Sattianayagam, Helen J Lachmann, Mark Offer, Julian D Gillmore, Philip N Hawkins, Ashutosh Wechalekar
Journal: Blood
Blood (2008) 112 (11): 1733.
https://doi.org/10.1182/blood.V112.11.1733.1733
Published: 2008
Journal Articles

Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report.

Ashutosh Wechalekar, Julian Gillmore, Helen Lachmann, Mark Offer, Philip Hawkins
Journal: Blood
Blood (2006) 108 (11): 129.
https://doi.org/10.1182/blood.V108.11.129.129
Published: 2006
Journal Articles

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

Clinical Trials & Observations
Ashutosh D. Wechalekar, Hugh J. B. Goodman, Helen J. Lachmann, Mark Offer, Philip N. Hawkins, Julian D. Gillmore
Journal: Blood
Blood (2006) 109 (2): 457–464.
https://doi.org/10.1182/blood-2006-07-035352
Published: 2006
Journal Articles

Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis

Brief Report
Julian D. Gillmore, Hugh J. Goodman, Helen J. Lachmann, Mark Offer, Ashutosh D. Wechalekar, Jayshree Joshi, Mark B. Pepys, Philip N. Hawkins
Journal: Blood
Blood (2006) 107 (3): 1227–1229.
https://doi.org/10.1182/blood-2005-08-3253
Published: 2006
Journal Articles

Standard Oral Melphalan Chemotherapy for AL Amyloidosis Revisited Using the Serum Free Light Chain Assay.

Mark Offer, Ashutosh D. Wechalekar, Hugh J.B. Goodman, Julian D. Gillmore, Helen J. Lachmann, Arthur R. Bradwell, Philip N. Hawkins
Journal: Blood
Blood (2005) 106 (11): 3495.
https://doi.org/10.1182/blood.V106.11.3495.3495
Published: 2005
Journal Articles

Efficacy of Risk Adapted Cyclophosphamide, Thalidomide and Dexamethasone in Systemic AL Amyloidosis.

Ashutosh D. Wechalekar, Hugh J.B. Goodman, Julian D. Gillmore, Helen J. Lachmann, Mark Offer, Arthur R. Bradwell, Philip N. Hawkins
Journal: Blood
Blood (2005) 106 (11): 3496.
https://doi.org/10.1182/blood.V106.11.3496.3496
Published: 2005
Journal Articles

The Role of Renal Transplantation in Systemic AL Amyloidosis.

Ashutosh D. Wechalekar, Helen J. Lachmann, Julian D. Gillmore, Hugh J.B. Goodman, Mark Offer, Philip N. Hawkins
Journal: Blood
Blood (2005) 106 (11): 3497.
https://doi.org/10.1182/blood.V106.11.3497.3497
Published: 2005
Journal Articles

Clinical Profile and Treatment Outcome in 92 Patients with AL Amyloidosis Associated with IgM Paraproteinaemia.

Ashutosh D. Wechalekar, Hugh J.B. Goodman, Julian D. Gillmore, Helen J. Lachmann, Mark Offer, Arthur R. Bradwell, Philip N. Hawkins
Journal: Blood
Blood (2005) 106 (11): 3498.
https://doi.org/10.1182/blood.V106.11.3498.3498
Published: 2005